• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Tivic adds new vagus nerve stim patent

Tivic adds new vagus nerve stim patent

May 13, 2025 By Carrie Pallardy

Tivic Health logoTivic Health Systems (Nasdaq:TIVC) filed a patent application for its vagus nerve stimulation (VNS) system.

Tivic has a portfolio of patients for its non-invasive VNS technology, and it aims to expand it with this new application. 

In July 2024, the health tech company added three patents granted in the U.S. and Europe, further shoring up its intellectual property portfolio. 

The new patent application, No. 63,801,058 filed with the United States Patent and Trademark Office, protects the therapeutics company’s approaches to personalized stimulation parameters and electrode positioning. 

“This patent protects key learnings from our VNS optimization study, which is advancing the science of vagus nerve interventions. In fact, we believe we are moving the needle on what will become the state-of-the art treatment approach by delivering much greater and more consistent therapeutic effects compared to what is currently available,” said Blake Gurfein, the company’s chief scientific officer. 

Tivic completed enrollment in a study of its VNS device in November 2024 with the aim of optimizing its approach and identifying the frequency and duration of treatment. 

In addition to its recent patent filing, the company met with leaders at the White House and Food and Drug Administration (FDA) in April. Tivic gave educational briefings on its clinical pipeline, including its non-invasive cervical VNS (ncVNS) technology. 

“We deeply appreciated the opportunity to discuss the importance of our clinical pipeline in potentially protecting and healing both active and retired military personnel, first responders, as well as U.S. citizens and our allies,” said Tivic CEO Jennifer Ernst. “While these meetings were informal in nature, we expect to continue these discussions as Entolimod and our ncVNS medical programs progress toward potential FDA approval.”

Tivic will report its first quarter 2025 results on May 15.

Carrie Pallardy is a freelance writer and editor based in Chicago. She has more than a decade of experience writing and reporting in the healthcare space.

Filed Under: Neurological, Neuromodulation/Neurostimulation Tagged With: intellectual property, Tivic Health Systems

More recent news

  • Siemens Healthineers debuts Accela single-breath radiotherapy system
  • GE HealthCare hires chief AI officer from Medtronic
  • Former Teleflex CEO to lead Inspire competitor Nyxoah
  • Retired Stryker leader Tim Scannell dies at 62
  • HighLife raises more than $90M to advance its TMVR system

Primary Sidebar

Cart

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy